A senescence-responsive nanodrug amplifies radiotherapy efficacy

Area of Science:

• Oncology
• Nanotechnology
• Biomedical Engineering

Background:

• Radiotherapy (RT) is a primary cancer treatment, but its effectiveness is hindered by tumor resistance and damage to healthy tissues.
• Therapy-induced cellular senescence is a significant factor contributing to both resistance and off-target damage in radiotherapy.

Purpose of the Study:

• To develop a novel nanodrug, Lipo@ABT263@Au, combining a senolytic agent with a gold-shelled liposome.
• To investigate the potential of this nanodrug to overcome radiotherapy resistance and mitigate associated toxicities.

Main Methods:

• High-throughput screening and transcriptomic analysis to identify RT-induced vulnerabilities.
• In vitro and in vivo studies using the Lipo@ABT263@Au nanodrug in cancer models.
• Evaluation of nanodrug efficacy in eliminating senescent cells, enhancing apoptosis, and suppressing the senescence-associated secretory phenotype (SASP).

Main Results:

• Lipo@ABT263@Au effectively eliminated senescent tumor cells and fibroblasts in vitro and in vivo.
• The nanodrug enhanced radiotherapy-induced apoptosis and suppressed pro-tumorigenic SASP effects.
• In vivo, the nanodrug demonstrated efficient tumor accumulation, significant tumor growth inhibition, and mitigation of RT-induced skin fibrosis without systemic toxicity.

Conclusions:

• Lipo@ABT263@Au represents a promising "one-two punch" strategy for cancer radiotherapy.
• This nanodrug platform effectively targets senescent cells, enhancing therapeutic outcomes and reducing side effects.
• The findings suggest clinical relevance for advancing cancer treatment through improved radiotherapy strategies.